Reaction
Product Use In Unapproved Therapeutic Environment reporting signals
As of the last recalculation, Product Use In Unapproved Therapeutic Environment appears in 819 FAERS reports alongside 7 co-occurring drug terms. The strongest observed disproportionality signal is CABOTEGRAVIR (PRR 1,164.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Cabotegravir | 255 | 1,164.9 | 1,203.1 |
| Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate | 73 | 112.3 | 112.7 |
| Dolutegravir Sodium | 7 | 19.9 | 19.9 |
| Darunavir | 10 | 17.0 | 17.0 |
| Emtricitabine And Tenofovir Alafenamide | 7 | 15.8 | 15.8 |
| Botulinum Toxin Type A | 5 | 10.3 | 10.3 |
| Alpelisib | 3 | 8.8 | 8.8 |